| Size | Price | Stock | Qty |
|---|---|---|---|
| 5mg |
|
||
| 10mg |
|
||
| 25mg |
|
||
| 50mg |
|
||
| 100mg | |||
| Other Sizes |
| Targets |
TC-G 1006 targets sphingosine-1-phosphate receptor 1 (S1P1), a G protein-coupled receptor that regulates lymphocyte trafficking, vascular development, and immune responses. By activating S1P1, TC-G 1006 induces lymphocyte sequestration in lymph nodes, modulating immune responses. The compound has an EC50 of 18–35 nM for S1P1 and shows no activity on S1P3.
|
|---|---|
| ln Vitro |
In vitro, TC-G 1006 is a potent S1P1 agonist with an EC50 of 35 nM (or 18 nM in some studies). It selectively induces calcium mobilization in cells expressing S1P1 over cells expressing S1P2, S1P3, S1P4, or S1P5. The compound displays >100-fold selectivity against receptor subtypes S1P2-5.
|
| ln Vivo |
In vivo, TC-G 1006 is orally active and induces lymphocyte sequestration. By activating S1P1, the compound modulates immune responses and has potential applications in autoimmune diseases and transplant rejection. Its oral bioavailability and selectivity make it a valuable tool for studying S1P1-mediated immune regulation.
|
| Enzyme Assay |
In vitro receptor binding assays for TC-G 1006 measure its affinity for S1P1 and selectivity over S1P2-5 using radioligand displacement techniques. Functional assays measure calcium mobilization in cells expressing S1P1, with an EC50 of 35 nM. Selectivity is confirmed by testing against S1P2, S1P3, S1P4, and S1P5.
|
| Cell Assay |
In vitro cell-based assays for TC-G 1006 use cells expressing S1P1, S1P2, S1P3, S1P4, or S1P5. Cells are treated with serial dilutions of the compound, and calcium mobilization is measured using fluorescent calcium indicators. The EC50 for S1P1 activation is calculated from dose-response curves, and selectivity over other S1P receptors is determined.
|
| Animal Protocol |
In vivo animal models for TC-G 1006 include models of autoimmune diseases such as experimental autoimmune encephalomyelitis (EAE) or transplant rejection. The compound is administered orally, and its effects on lymphocyte counts, immune responses, and disease progression are evaluated. Pharmacodynamic studies measure S1P1 activation and lymphocyte sequestration in lymph nodes.
|
| ADME/Pharmacokinetics |
TC-G 1006 has a molecular formula of C21H16F3N3O3 and a molecular weight of 415.37 g/mol. It is a white solid stored at -20°C. The compound is soluble in DMSO and has a purity of >98%. It is also known as S1P1 Agonist III and S1P1 agonist III.
|
| Toxicity/Toxicokinetics |
The toxicity profile of TC-G 1006 is characterized in preclinical safety studies. As an S1P1 agonist, the compound may affect immune function and lymphocyte trafficking. The compound is for research use only and is not approved for clinical use. Appropriate safety precautions should be taken during handling.
|
| References | |
| Additional Infomation |
TC-G 1006 is a potent and selective sphingosine-1-phosphate receptor 1 (S1P1) agonist with an EC50 of 35 nM (or 18 nM). It displays >100-fold selectivity against receptor subtypes S1P2-5. TC-G 1006 is orally active and induces lymphocyte sequestration. The compound is also known as S1P1 Agonist III and is intended for laboratory research use only.
|
| Molecular Formula |
C21H16F3N3O3
|
|---|---|
| Molecular Weight |
415.37
|
| Exact Mass |
415.114
|
| CAS # |
1324003-64-6
|
| PubChem CID |
54764919
|
| Appearance |
White to off-white solid powder
|
| LogP |
5.201
|
| Hydrogen Bond Donor Count |
2
|
| Hydrogen Bond Acceptor Count |
7
|
| Rotatable Bond Count |
4
|
| Heavy Atom Count |
30
|
| Complexity |
596
|
| Defined Atom Stereocenter Count |
0
|
| SMILES |
COC1=C(C=NC=C1)C(=O)NC(=O)NC2=CC(=C(C=C2)C3=CC=CC=C3)C(F)(F)F
|
| InChi Key |
MLDQTQOMWDNTNN-UHFFFAOYSA-N
|
| InChi Code |
InChI=1S/C21H16F3N3O3/c1-30-18-9-10-25-12-16(18)19(28)27-20(29)26-14-7-8-15(13-5-3-2-4-6-13)17(11-14)21(22,23)24/h2-12H,1H3,(H2,26,27,28,29)
|
| Chemical Name |
4-methoxy-N-[[4-phenyl-3-(trifluoromethyl)phenyl]carbamoyl]pyridine-3-carboxamide
|
| Synonyms |
TCG1006 TC G 1006 TC-G 1006
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
DMSO : ~62.5 mg/mL (~150.47 mM)
|
|---|---|
| Solubility (In Vivo) |
Solubility in Formulation 1: ≥ 2.08 mg/mL (5.01 mM) (saturation unknown) in 10% DMSO + 40% PEG300 + 5% Tween80 + 45% Saline (add these co-solvents sequentially from left to right, and one by one), clear solution.
For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 20.8 mg/mL clear DMSO stock solution to 400 μL PEG300 and mix evenly; then add 50 μL Tween-80 to the above solution and mix evenly; then add 450 μL normal saline to adjust the volume to 1 mL. Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH₂ O to obtain a clear solution. Solubility in Formulation 2: ≥ 2.08 mg/mL (5.01 mM) (saturation unknown) in 10% DMSO + 90% (20% SBE-β-CD in Saline) (add these co-solvents sequentially from left to right, and one by one), clear solution. For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 20.8 mg/mL clear DMSO stock solution to 900 μL of 20% SBE-β-CD physiological saline solution and mix evenly. Preparation of 20% SBE-β-CD in Saline (4°C，1 week): Dissolve 2 g SBE-β-CD in 10 mL saline to obtain a clear solution. View More
Solubility in Formulation 3: ≥ 2.08 mg/mL (5.01 mM) (saturation unknown) in 10% DMSO + 90% Corn Oil (add these co-solvents sequentially from left to right, and one by one), clear solution. |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 2.4075 mL | 12.0375 mL | 24.0749 mL | |
| 5 mM | 0.4815 mL | 2.4075 mL | 4.8150 mL | |
| 10 mM | 0.2407 mL | 1.2037 mL | 2.4075 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
